LiverLearning®: 2019 Hans Popper Basic Science State-of-the-Art Lecture: Distributed Hepatocytes in Liver Homeostasis and Regeneration

The annual Hans Popper Lecture clarifies exciting new findings on cellular renewal mechanisms in liver disease and liver cancer. A subset of hepatocytes with high levels of telomerase are distributed throughout the liver lobule, serving to renew the organ during homeostasis and in response to injury. Learn how genetic ablation of these hepatocytes results in scarring and defective regenrative responses.

LiverLearning®: 2019 Emerging Trends Symposium: Microelimination of Viral Hepatitis

HCV-infected organs are now being used for transplantation to HCV-uninfected recipients. This program will review existing data on both liver and non-liver transplantation from HCV-positive donors to HCV-negative recipients and key ethical and practical issues related to HCV-infected donor organs, including whether this should be done only in clinical trials or could be accepted as standard of care.

LiverLearning®: Liver Transplantation and Surgery SIG & Pediatric Liver Disorders SIG: Optimizing Allograft Health Over a Lifetime

Discover how allocation impacts long-term outcomes for the transplant recipient and liver graft at this session. Speakers will address ways to improve the ability to interpret and identify the significance of long-term, post-transplant liver biopsy findings and offer tools to expand one’s perspective on individualizing immunosuppression to optimize long-term outcomes for the allograft and recipient.

LiverLearning®: 2019 Advances for Practitioners: New AASLD Guidelines: Updated Recommendations and Ongoing Challenges in HCC, PBC and ALD

AASLD Guideline/Guidance Statements on treating hepatocellular carcinoma (HCC), primary biliary cholangitis (PBC) and alcohol-related liver disease (ALD) are now updated to reflect data published since 2010, when the previous versions were released. At this session, the guidelines’ authors will highlight important changes hepatologists should know and discuss controversial or challenging issues in treating patients with these chronic liver diseases.

Reply:

Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly Watt, Samuel S. Lee, the Cirrhotic Cardiomyopathy Consortium: The Cirrhotic Cardiomyopathy Consortium is a multidisciplinary international group whose focus is to improve the understanding of cirrhotic cardiomyopathy, its management and outcomes – 11 November 2019

LiverLearning®: 2019 President's Choice Lecture

In the world's poorest nations, the appalling loss of life from easily treated or preventable illnesses represents a moral tragedy. This year's President's Choice Lecture explores potential strategies to correct this inequity, including collaborative partnerships among medical professionals, ways to accurately measure the impact of global disease management efforts and the innovative solutions necessary to accomplish this great task.

Subscribe to